Living Cell Technologies annual loss widens by a third on drug trial costs

Living Cell Technologies annual loss widens by a third on drug trial costs
Rebecca Howard
By Rebecca Howard Aug. 24 (BusinessDesk) - Living Cell Technologies, the ASX-listed biotech company with New Zealand-based operations, said its full-year loss was 33 percent wider on higher costs associated with its latest drug trials.  The Melbourne-based company reported a net loss of A$4.09 million, or 76 cents per share, in the year to June 30 versus a loss of A$3.09 million, or 69 cents, a year earlier.  Living Cell Technologies has developed a treatment for Parkinson’s disease using choroid plexus brain cells from neonatal pigs,...